Investment Considerations
- INBS offers a patented, non-invasive testing solution positioned to disrupt a global drug screening market projected to reach $14.9 billion by 2030.
- The company is revenue-generating, with 148% year-over-year growth in FY 2024 and 450+ active customer accounts.
- Its Intelligent Fingerprinting system provides rapid, on-site results with a lower cost and higher convenience compared to traditional methods.
- The Intelligent Fingerprinting Drug Screening System is already in commercial use internationally, and a U.S. product launch is planned for 2025, with FDA 510(k) clearance in process and new patent protections underway.
- INBS is led by a seasoned executive team with global healthcare and commercialization experience.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings such as opiates, cocaine, methamphetamine, and cannabis. This innovative approach positions INBS to transform drug testing protocols, particularly in industries where safety and speed are mission critical.
The company’s vision is to redefine drug screening by removing the pain points of traditional testing methods, including biohazardous waste, privacy concerns, and long result turnaround times. With results in under 10 minutes and no need for gender-specific collectors or laboratory facilities, the system empowers companies and organizations to screen more efficiently. INBS continues to drive adoption in international markets, with customers spanning construction, logistics, healthcare, government, and drug treatment sectors.
INBS’s mission is centered on delivering accessible, transformative solutions that improve lives and operational safety. As the company expands toward a planned U.S. market launch in 2025, it is also strengthening its intellectual property portfolio and localizing solutions for Spanish-speaking regions.
The company is headquartered in New York, New York.
Intelligent Fingerprinting Drug Screening System
Intelligent Bio Solutions’ flagship offering is the Intelligent Fingerprinting Drug Screening System, a portable, three-part solution that includes a fingerprint collection cartridge, a lateral flow-based DSR-Plus reader, and software for rapid drug screening. Designed to be used on-site, this system eliminates the complexities and hazards of urine and saliva tests, offering a clean, fast, and non-invasive alternative.
The system screens for a broad range of substances including opiates, methamphetamine, cocaine, cannabis, benzodiazepines, and more. Its cost advantage is significant — point-of-care fingerprint tests cost approximately $20, compared to $300 for typical urine or saliva testing. The platform includes over 1,000 DSR-Plus Readers installed across customer sites, supporting a base of more than 450 active customer accounts globally. In clinical studies, the system demonstrated 94.1% accuracy and 100% specificity, providing a credible foundation for future FDA approvals and market expansion.
In addition to drug screening, INBS is developing a proprietary biosensor platform designed to detect specific biomarkers from non-invasive samples such as sweat, saliva, and interstitial fluid. These additional applications remain under development.
Market Opportunity
Intelligent Bio Solutions operates at the intersection of workplace safety, public health, and diagnostic innovation. The company is targeting the drug screening products market, which is projected to reach $14.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 12.1%, according to Research and Markets.
In the U.S., substance abuse is a $400 billion issue, with more than 70% of individuals using illicit drugs or alcohol currently employed. This presents an urgent need for scalable, workplace-compatible screening technologies. Industries such as transportation, construction, mining, and healthcare are among the highest adopters of employee drug testing protocols, driven by regulatory requirements and safety imperatives.
INBS’s non-invasive solution is well-positioned to capitalize on trends toward less invasive, faster, and more convenient testing methods — potentially displacing legacy systems reliant on urine or saliva testing, which have longer turnaround times and greater administrative burdens.
Leadership Team
Harry Simeonidis, Chief Executive Officer, has over 25 years of experience across the healthcare, pharmaceutical, and life sciences industries. He previously served as General Manager for Surgery, Asia Pacific at GE Healthcare. Prior to that, he was President and CEO of GE Healthcare ANZ, where he led significant market share growth.
Spiro Sakiris, Chief Financial Officer, brings 34 years of expertise in accounting, taxation, IPO preparation, and capital raising. He is highly experienced with IFRS and U.S. GAAP applications in the life sciences sector and is a member of the Institute of Chartered Accountants of Australia & New Zealand.